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Summary Immunoliposomes were prepared by conjugating anti-carcinoembryonic antige (CEA) monoclonal antibody with liposomes
containing [10B]compound. These immunoliposomes were shown to bind selectively to human pancreatic carcinoma cells (AsPC-1) bearing
CEA on their surface. The cytotoxic effects of locally injected [1'B]compound, multilamellar liposomes containing [10B]compound or
[10B]immunoliposomes (anti-CEA) on human pancreatic carcinoma xenografts in nude mice were evaluated with thermal neutron irradiation.
After thermal neutron irradiation of mice injected with [10B]solution, 10B-containing liposomes or [10B]immunoliposomes, AsPC-1 tumour
growth was suppressed relative to controls. Injection of [10B]immunoliposomes caused the greatest tumour suppression with thermal neutron
irradiation in vivo. Histopathologically, hyalinization and necrosis were found in '0B-treated tumours, while tumourtissue injected with saline or
saline-containing immunoliposomes showed neither destruction nor necrosis. These results suggest that intratumoral injection of boronated
immunoliposomes can increase the retention of '0B atoms by tumour cells, causing tumour growth suppression in vivo upon thermal neutron
irradiation. Boron neutron capture therapy (BNCT) with intratumoral injection of immunoliposomes is able to destroy malignant cells in the
marginal portion between normal tissues and cancer tissues from the side of 4He generation.
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Boron neutron capture therapy (BNCT) is aimed at inhibiting the
growth of various cancers (Mishima et al, 1989a; Hatanaka and
Nakagawa, 1994). The cytotoxic effect of BNCT is caused by a
nuclear reaction between '°B and thermal neutrons (Locher, 1936;
Kruger, 1940). This nuclear reaction is as follows:
'°B + 'n -* "B -* 7Li + 4He (a) + 2.79 MeV
The resultant lithium ions and a particles are high linear energy
transfer particles with relatively high biological efficiency.
Moreover, their short range in tissue (5-9 jum) restricts radiation
damage to those cells in which boron is located at the time of
neutron irradiation. Therefore, it is theoretically possible to kill
tumour cells without affecting adjacent healthy cells, if '°B atoms
can be accumulated selectively in tumour cells. BNCT has been
used clinically in patients with malignant brain tumours (Dom,
1994; Hatanaka and Nakagawa, 1994) and melanoma (Mishima et
al, 1989a,b).
Liposomes are useful drug carriers (Bangham et al, 1965;
Hashimoto et al, 1983; Konno et al, 1987; Singh et al, 1989;
Tomita et al, 1989; Feakes et al, 1993), and it is possible to carry a
large amount of ['°B]compound in a liposome, which may be
delivered to a tumour cell. We have reported that '°B atoms deliv-
ered by immunoliposomes are cytotoxic to human pancreatic
carcinoma cells (AsPC-1) with thermal neutron irradiation in vitro
(Yanagie et al, 1991).
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Multilamellar vesical immunoliposomes are easily phagocy-
tozedby thereticuloendothelial system (RES), so it is very difficult
to accumulate the liposomal contents in the target cancers. Because
of this, intravenous injections are no longer used in clinical prac-
tice, percutaneous echoic intratumoral injection or transarterial
embolization (TAE) are preferred (Hasuike et al, 1992).
In this report, we prepared ['0B]compound solutions in several
concentrations and multilamellar liposomes containing ['0B]-
compound or ['0B]immunoliposomes. Intratumoral injection of
'°B solutions, boronated liposomes and ['°B]immunoliposomes all
inhibited tumour cell growth with thermal neutron irradiation in
vivo. The ['°B]immunoliposomes showed the strongest suppres-
sion oftumour growth in the '°B treated groups. BNCT with intra-
tumoral injection of immunoliposomes with a high content of
['0B]compound has the ability to destroy malignant cells at the
edge ofthe tumour mass.
MATERIALS AND METHODS
Chemicals
The caesium salt of undecahydro-mercaptocloso-dodecaborate
(Cs2'°B12H,,SH) was kindly supplied by Shionogi Research
Laboratories Co. Ltd. (Osaka, Japan). The solubility of the
compound in water was 250 mm at 40°C.
Egg yolk phosphatidylcholine (Egg PC) was a gift from Nippon
Fine Chemical Co. (Osaka, Japan). Cholesterol was obtained from
Sigma Chemical Co. Ltd. (St Louis, MO, USA). Dipalmitoyl-
phosphatidyl-ethanolamine (DPPE) was from Calbiochem-
Behring (San Diego, CA, USA). N-hydroxy-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) was purchased from Pharmacia
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Figure 1 (A) Effects of ['°B]compound administered in several
concentrations on the growth of AsPC-1 inoculated into the backs of BALB/c
nu/nu mice (n = 10). Results are expressed as relative mean tumour volumes
(ViNo), where Vi is the tumour volume at a given time and Vo is the volume
at the initiation of treatment. Tumour volume was calculated as 1/2 x length x
width2. Fourteen days after inoculation of AsPC-1 cells, 'OB solutions (500,
1000 or 2000 p.p.m.), boronated liposomes or saline were injected into
tumours. Mice were irradiated after injection with 2 x 1012 n cm-2 thermal
neutrons: 500 p.p.m. (DE-), 1000 p.p.m. (A-A), 2000 p.p.m. (O-O) and
saline (A-4). Values are expressed as means + s.d. (B) Growth inhibition of
AsPC-1 cells treated with boronated liposomes. After inoculation of AsPC-1
(n = 10), saline (0-.), 2000 p.p.m. '°B solution (A-A) or boronated
liposomes (O-O) were injected into the tumours. The amount of '°B in
liposomes prepared with 250 mm ['°B] compound was 782 p.p.m. (mean).
After injection, mice were irradiated with 2 x 1012 n cm-2 thermal neutrons.
The results are expressed as relative mean tumour volume, as in (A). Values
are the means ± s.d. (C) Growth inhibition of AsPC-1 cells treated with
boronated a-CEA immunoliposomes. After inoculation of AsPC-1 (n = 10),
boronated liposomes (AL-A), boronated a-CEA immunoliposomes (0- )
or saline-entrapped a-CEA immunoliposomes as controls (@-.*) were
injected into the tumours. After injection, mice were irradiated with 2 x 1012
n cm-2 thermal neutrons. The results are expressed as relative mean tumour
volume. Values are the means ± s.d.
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Figure 2 (A) Morphological findings of tumours at 30 days after BNCT.
Mice were injected intratumorally with [10B]immunoliposomes and irradiated
with 2 x 1012 n cm-2 thermal neutrons. Top, saline-entrapped a-CEA
immunoliposomes (10B 0 p.p.m.); middle, boronated liposomes; bottom,
boronated a-CEA immunoliposomes. The amount of '°B in liposomes
prepared with 250 mm ['°B]compound was 782 p.p.m. (mean). (B)
Pathological findings of tumours after BNCT. Left, saline-entrapped a-CEA
immunoliposomes (10B :0 p.p.m.); centre boronated liposomes; right,
boronated ax-CEA immunoliposomes. Original magnification x 200
Fine Chemicals (Uppsala, Sweden); a stock solution (30 mM)
in ethanol was stored at -20°C. Dithiothreitol was obtained
from Sigma. 3-(2-pyridyldithio) propionyl-dipalmitoyl-phos-
phatidylethanolamine (DTP-DPPE) was prepared by reacting
SPDP with DPPE as described by Barbet et al (1981).
Target tumour cells and mice
The human pancreatic carcinoma cell line AsPC-1 (Chen, 1982),
which produces carcinoembryonic antigen (CEA) (Gold and
Freedman, 1965), was obtained from Dainihon Seiyaku Co. Ltd.
(Osaka, Japan). AsPC-1 was maintained in RPMI-1640 medium
(Hazleton Biologics, Kansas, USA), supplemented with 10% fetal
calf serum (Cell Culture Laboratories, Ohio, USA) and 100 ,ug
ml-1 kanamycin. All cultures were incubated in air with a high
moisture content and 5% carbon dioxide at 370C. The medium was
routinely changed three times a week.
Male BALB/c nulnu mice were obtained from Nihon SLC
(Shizuoka, Japan) and used at 6-7 weeks of age. In each experi-
ment, mice of similar age and weight were selected. Mice were
housed in plastic cages and maintained in an air-conditioned room.
The procedures for tumour implantation and sacrifice of the
animals were in accordance with approved guidelines of the
Institution's Animal Ethics Committee.
Preparation of anti-human CEA monoclonal antibody
Detailed procedures for the preparation of the anti-human CEA
monoclonal antibody have been described (Yanagie et al, 1991).
Briefly, a cell clone, 2C-8, which secretes anti-human CEA mono-
clonal antibody, was established from somatic cell hybrids
between mouse myeloma cells (X63, Ag8 and 653) and spleen
cells of a BALB/c mouse that was hyperimmune to AsPC-1. The
2C-8 Ig G antibody was purified on a DEAE-52 cellulose column.
The epitope recognized by the antibody was confirmed to be the
200-kDa CEA and 45-kDa non-specific cross-reacting antigen
(NCA) by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blotting.
Preparation of liposomes containing [10B]compound
Egg yolk PC (5 ,umol), cholesterol (5 ,umol) and DTP-DPPE (0.25
,umol) were dissolved in chloroform-methanol (2:1) and mixed in
a conical flask. The organic solvent was removed by evaporation
at 40°C. An aliquot of0.5 ml of250 mM ['0B]compound (Cs2'°B,2
H,USH) solution was added to the dried lipid film, and multil-
amellar vesicles were prepared by vortex dispersion (Tomita et al,
1989). Uncapsulated ['0B]compound was removed by centrifuga-
tion at 20 000g.
Conjugation of the monoclonal antibody to the
liposomal surface
Liposomes were centrifuged at 20 000g after treatment for 30 min
at room temperature with 20 mm dithiothreitol to ensure functional
SH-groups (Yanagie et al, 1991). A sample of 1 ml ofmonoclonal
antibody (4.0 mg ml-') was incubated with an excess amount of
SPDP for 30 min at room temperature. Afterremoval offree SPDP
by passage through a Sephadex G 25 column, liposomes were
suspended in the antibody solution. Following incubation at 4°C
overnight, the boronated immunoliposomes were washed by
centrifugation at 20 000g and suspended in 1 ml of 10 mM veronal
buffer, pH 7.4, supplemented with 0.4% gelatin (Yanagie et al,
1991). A prompt-gamma boron analysis technique was used to
measure the 478 keV y-photons produced during the '°B (n, a) 7Li
reaction; this determines the boron content conjugated with anti-
CEA monoclonal antibody and entrapped in liposomes and
immunoliposomes (Kobayashi and Kanda, 1983).
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Gamma-irradiation of cells
Cells irradiated with thermal neutrons were also irradiated with
various doses ofgamma rays generated concomitantly and depen-
dent on the neutron dose. Detailed procedures for the estimation of
the effect ofgamma rays generated by thermal neutrons have been
described (Yanagie et al, 1991). Briefly, AsPC-1 cells were
exposed to gamma rays from a 137Cs source in a Gamma Cell 40
(Atomic Energy of Canada, Ottawa, Canada) equivalent to the
fluences of thermal neutron irradiation in an atomic reactor
(ICRU, 1964). After irradiation, 0.25 ,uCi [3H]TdR was added to
each well and incubated for 8 h. The incorporated thymidine was
quantified in a liquid scintillation spectrometer. Thermal neutron
fluences (2 x 1012 and 5 x 1012 n cm-2) generated 1.03 and 3.36 Gy
ofgamma ray, respectively, in the thermal column ofthe TRIGA-
II reactor. Doses less than 1.03 Gy of gamma rays had no
inhibitory effect on AsPC-1 cell growth. Since the growth of
AsPC-1 cells was weakly suppressed by 3.36 Gy gamma ray,
thermal neutron fluences less than 2 x 10l2 n cm-2 were used in the
in vivo experiment.
Thermal neutron irradiation
In vitro experiments
Detailed procedures for boron neutron capture have been
described previously (Yanagie et al, 1991). Briefly, AsPc-1 cells
were incubated in a 96-well microplate at 37°C in 5% carbon
dioxide in air for 8 h in the presence of boronated anti-CEA or
['°B]immunoliposomes. After washing, the cells were irradiated
with thermal neutrons at the TRIGA-Il atomic reactor of Rikkyo
University. After irradiation, 0.25 gCi [3H]TdR was added to each
well and incubated for 8 h. The incorporated thymidine was then
measured as above.
In vivo experiments
AsPC-1 cells (1 x 107) were injected subcutaneously into the back
of male BALB/c nu/nu mice. At 10-14 days after injection, when
the estimated tumour weight reached 100-300 mg, 0.2 ml of 10B
solution (0, 500, 1000, or 2000 p.p.m.), boronated liposomes or
boronated immunoliposomes were injected directly into the
tumours. One hour after injection, mice were irradiated for 37 min
with 9 x 108 ns-1 cm2 thermal neutrons (total fluence: 2 x 1012 n
cm-2) at the TRIGA-II atomic reactor. After irradiation, the effect
ofBNCT was evaluated on the basis oftumourvolume (calculated
as 1/2 x length x width2) and histological findings of the tumours
at 3-day intervals (Konno et al, 1987). Boron concentrations of
tumours and blood were analysed by prompt-gamma boron
analysis technique (Kobayashi and Kanda, 1983).
RESULTS
Growth inhibition of tumour treated with '0B solutions
In order to examine the therapeutic effect of '°B solutions on the
growth ofAsPC-l cells,tumour-bearing mice (n = 10) were injected
intratumorally with '0B solutions. The concentrations of '°B solu-
tions were 0 (control,saline),500, 1000 and 2000p.p.m. Afterinjec-
tion, mice were irradiated with 2 x 1012 n cm-2 thermal neutrons. As
shown in Figure IA, significant inhibition of tumour growth was
observed in all three groups treated with '°B solutions compared
with the control group. The inhibition was dose dependent.
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Figure 3 (A) Comparison of boronated antibody and immunoliposomes on
growth inhibition of AsPC-1 in vitro. Immunoliposomes were prepared with
250 mm ['°B]compound and 4 mg ml-1 anti-CEA. Cytotoxicity was estimated
by [3H]TdR incorporation. Each point represents the mean ± s.d. of triplicate
assays. AsPC-1 cells were treated with boronated a-CEA monoclonal
antibody (4 mg ml-') (A-A) or boronated a-CEA immunoliposomes
(O-0). The growth of irradiated cells without MAb or immunoliposome
treatment (X---- -X) served as a control. (B) Comparison of boronated
antibody and immunoliposomes on growth inhibition of AsPC-1 in vivo. After
inoculation of AsPC-1 (n = 10), boronated a-CEA monoclonal antibody
(E-F), boronated a-CEA immunoliposomes (O-O), a-CEA monoclonal
antibody (A-A) and saline-entrapped a-CEA immunoliposomes (-4*)
were injected. Mice were then irradiated with 2 x 1012 n cm-2 thermal
neutrons. Values are the means ± s.d.
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Growth inhibition of tumour treated with boronated
liposomes
The effect of ['0B]compound entrapped in liposomes on AsPC-1 cell
growth was examined with thermal neutron irradiation. Liposomes
were prepared with 250 mi [10B]compound. The amount of '°B in
liposomes was 782.77 ± 34.40 (mean ± s.d.) jig ml-1 liposome by
prompt-gamma boron analysis technique. As shown in Figure lB,
intratumoral injection of these liposomes inhibited tumour cell
growth to the same extent as 2000 p.p.m. of '°B.
Effect of ['°B]immunoliposome on growth inhibition of
tumour
In order to examine the therapeutic effect of [10B]immunolipo-
somes on the growth of AsPC-1 cells, tumour-bearing mice were
injected intratumorally with liposomes prepared with 250 mM
['0B]compound and 4 mg ml-' anti-CEA, liposomes prepared with
['°B]compound only or liposomes prepared with anti-CEA only.
After intratumoral injection of ['°B]immunoliposomes, we found
boron concentrations in tumour tissue and blood of 49.59 ± 6.59
p.p.m. and 0.30 ± 0.08 p.p.m. respectively. After injection, the
mice were irradiated with 2 x 1012 n cm-2 thermal neutrons. As
shown in Figure IC, tumour growth after BNCT using intratu-
moral injection of ['°B]immunoliposomes had been suppressed,
the tumour had not regrown and became necrotic as shown Figure
2A (bottom). The control group treated with saline-entrapped
immunoliposomes showed no inhibition ofgrowth.
Morphological and pathological findings of tumour
treated with [10B]immunoliposomes
The therapeutic effects of ['0B]immunoliposomes were clear from
the morphological and pathological findings. As shown in Figure
2, the tumour mass became necrotic and the increment in tumour
volume was suppressed in the groups treated with ['0B]liposomes
and [10B]immunoliposomes, while tumour in the control group
('0B: 0 p.p.m.) continued to grow. The histology of tumours after
BNCT showed necrosis and hyalinization.
Comparison of boronated antibody and
immunoliposomes on growth inhibition of AsPC-1 in
vitro
In order to compare the effect of boronated antibody or that of
immunoliposomes on the growth of AsPC-1, the cells were treated
with 4mg ml-' anti-CEA monoclonal antibody reacted with 250 mM
['0B]compound or liposomes prepared with 250 mm ['0B]compound
and 4 mg ml-' anti-CEA. The amount of '°B conjugated with anti-
CEA was 73.35 ± 13.90 jig ml',and the amount of 10B entrapped in
immunoliposomes was 782.77 ± 34.40 jig ml-' by prompt-gamma
boron analysis technique. Cells were then irradiated with thermal
neutrons and cultured in vitro. As shown in Figure 3A,AsPC-1 cells
treated with boronated anti-CEA and ['°B]immunoliposomes
showed a reduction in growth by 63% and 35%, respectively,
compared with untreated cells at> 1 x 1012 fluence.
Comparison of boronated antibody and
immunoliposomes on growth inhibition of tumour in
vivo
Tumour-bearing mice (n = 10) were injected with boronated anti-
CEA or ['°B]immunoliposomes intratumorally. After injection,
mice were irradiated with 2 x 1012 n cm-2 thermal neutrons. As
shown in Figure 3B, tumour growth after boronated anti-CEA and
['B]immunoliposome treatment was suppressed by 51% and 26%,
respectively, compared with the control. Tumours treated with
anti-CEA alone showed no suppression.
DISCUSSION
We have previously shown that boronated immunoliposomes attach
to AsPC-1 tumour cells and suppress their growth in vitro after
thermal neutron irradiation (Yanagie et al, 1991). Suppression was
dependent upon the concentration ofthe [10B]compound in the lipo-
somes and on the density of antibody conjugated to the liposomes.
Drugs encapsulated in liposomes are protected from enzymatic
attack or immune reaction until they are released (Gabizon and
Papahadjopoulos, 1988). Administration of liposomes in vivo is
usually non-toxic (Hughes et al, 1989), since they are composed of
biodegradable lipids. Immunoliposomes targeted to a specific
organ may deliver a high concentration ofthe encapsulated drug to
the organ (Leserman et al, 1981). Drugs released from immunoli-
posomes can reach target cells by free diffusion over a relatively
short distance, thereby producing a localized high dose essential
for cytotoxicity. The immunoliposome could serve as a local depot
for sustained drug release. An increase in the number of antibody
molecules per liposome will prolong the retention ofthe immuno-
liposome in the target organ (Hughes et al, 1989).
In the present experiment, intratumoral injection of '0B solu-
tions, boronated liposomes or boronated anti-CEA immunolipo-
somes suppressed tumour cell growth in vivo with thermal neutron
irradiation. Tumours became necrotic and stopped growing for a
while. Inhibition of tumour growth after injection of boronated
liposomes was dependent upon the concentration of ['0B]-
compound in the solution. Liposomes have the capacity for
keeping high concentrations of ['0B]compound in the tumour. In
our experiments, cytotoxicity of the '0B (n, a) 7Li neutron capture
reaction using the ['0B]immunoliposomes was greater than using
antibody-free [10B]liposomes. This result suggests that immunoli-
posomes containing [10B]compounds can be applied to BNCT as
effective carriers ofthose compounds to target cells.
BNCT is dependent on the absolute amount and location of
boron in the tumour as well as the tumour-blood and tumour-
normal tissue boron concentration ratios. Effective BNCT requires
the delivery of a considerable amount (> 15 p.p.m.) of '0B into the
targeted malignant tissue (Coderre et al, 1990). Selective tissue
cytotoxicity can be achieved in tissues containing '°B that receive
irradiation with thermal neutrons. a-Particles and 7Li recoil nuclei
have a very high linear energy transfer, resulting in the rapid
transfer oftheir energy to cells within a diameter ofapproximately
12gm. This energy transfer is highly destructive to critical molec-
ular targets, such as nuclear DNA. Therefore, it is desirable to
achieve a high gradient between the '°B concentration in tumour
compared with adjacent healthy tissues.
Studies in animal models indicate that tumour uptake after
administration of the sulphydryl borane dimer (Na410B24H22S2 is
about twice the tumour uptake after administration of equal
amounts of boron as a monomer (Joel et al, 1989, 1990). It was
observed that the decrease in tumour boron concentration is much
slower after infusion of dimer than with monomer. Mercapto-
undecahydrododecaborate sodium (Na2'B12H1SH; BSH) may be
oxidized to a dimer and react with disulphide-containing proteins.
Joel et al (1989, 1990) measured the '0B concentrations in the
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tumours by prompt-gamma spectrometry. The boron-containing
amino acid analogue, boronophenylalanine (BPA) has been shown
to deliver boron selectively to melanoma tissue (Mishima et al,
1989b). BPA has been successful in animal models and has
recently been used in Japan in human trials of BNCT for
melanoma (Mishima et al, 1989a). In a study of BPA distribution
in a rat glioblastoma, Coderre et al (1990, 1994) demonstrated a
tumour-blood ratio of 4:1 compared with 0.7:1 for BSH. Ratios
as high as 400:1 in tumour compared with normal brain were
obtained 48 h after intravenous injection of 100 mg kg-' BOPP,
while at the same time point, the tumour-blood ratio was only 11:1
(Hill et al, 1992; Malleshe et al, 1993).
Damage to brain endothelium may present particular problems,
if reactor exposures take place when blood boron levels are high
(Joel et al, 1990). Thus, it is critical to accumulate ['0B]compound
in the tumour mass by intratumoral injection and to avoid raising
the concentrations ofblood boron.
Most treatment failures are caused by local recurrence of the
tumour, suggesting that more aggressive local therapy could be
beneficial. BNCT using intratumoral injections of ['°B]immunoli-
posomes will be useful to control local recurrence with minimal
damage to adjacent normal tissue. There are several potential clin-
ical applications of ['0B]immunoliposomes for improving further
methods for inhibiting the uptake of intravenously administered
immunoliposomes by the reticuloendothelial system (RES). To
obviate phagocytosis by the RES, we have tried to prepare polyeth-
ylene glycol-coated immunoliposomes (stealth immunoliposomes)
(Maruyama et al, 1995). Experiments using systemic injection of
stealth immunoliposomes are in progress for selective targeting of
'°B atoms in tumours in the application of clinical BNCT.
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